- Home
- A-Z Publications
- Current Neuropharmacology
- Previous Issues
- Volume 16, Issue 6, 2018
Current Neuropharmacology - Volume 16, Issue 6, 2018
Volume 16, Issue 6, 2018
-
-
Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Authors: Sheikh A. Sehgal, Mirza A. Hammad, Rana Adnan Tahir, Hafiza Nisha Akram and Faheem AhmadBackground: As the number of elderly persons increases, neurodegenerative diseases are becoming ubiquitous. There is currently a great need for knowledge concerning management of oldage neurodegenerative diseases; the most important of which are: Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease. Objective: To summarize the potential of computationally predicted m Read More
-
-
-
In Silico Studies in Drug Research Against Neurodegenerative Diseases
Authors: Farahnaz R. Makhouri and Jahan B. GhasemiBackground: Neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis, Parkinson's disease (PD), spinal cerebellar ataxias, and spinal and bulbar muscular atrophy are described by slow and selective degeneration of neurons and axons in the central nervous system (CNS) and constitute one of the major challenges of modern medicine. Computeraided or in silico drug design methods Read More
-
-
-
Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design
Authors: Akhil Kumar, Ashish Tiwari and Ashok SharmaAlzheimer disease (AD) is now considered as a multifactorial neurodegenerative disorder and rapidly increasing to an alarming situation and causing higher death rate. One target one ligand hypothesis does not provide complete solution of AD due to multifactorial nature of the disease and one target one drug fails to provide better treatment against AD. Moreover, currently available treatments are limited and most of t Read More
-
-
-
Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders
Authors: Mohammad H. Baig, Khurshid Ahmad, Gulam Rabbani, Mohd Danishuddin and Inho ChoiBackground: Neurodegenerative disorders (NDs) are diverse group of disorders characterized by escalating loss of neurons (structural and functional). The development of potential therapeutics for NDs presents an important challenge, as traditional treatments are inefficient and usually are unable to stop or retard the process of neurodegeneration. Computer-Aided Drug Design (CADD) has emerged as an efficient mean Read More
-
-
-
QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases
Authors: Michelle F. Correa and Joao Paulo dos Santos FernandesBackground: Histamine H3 receptor (H3R) is associated with several neuropsychological diseases, and thus it is an important target involved in several CNS disorders, such as narcolepsy, attention deficit hyperactivity disorder and schizophrenia. Since QSAR modeling is a feasible approach to explain the role of the molecular substituents in the biological activity, it can help in improving the design of better H3R ligands for the Read More
-
-
-
Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease
Authors: Hui Li, Xiaobing Wang, Hongmei Yu, Jing Zhu, Hongtao Jin, Aiping Wang and Zhaogang YangBackground: Alzheimer's disease (AD) as the most common cause of dementia among older people has aroused the universal concern of the whole world. However, until now there is still none effective treatments. Consequently, the development of new drugs targeting this complicated brain disorder is urgent and needs more efforts. In this review, we detailed the current state of knowledge about new candidate drugs targeti Read More
-
-
-
Blood Brain Barrier and Alzheimer's Disease: Similarity and Dissimilarity of Molecular Alerts
Authors: Alla P. Toropova, Andrey A. Toropov, Sanija Begum and Patnala G.R. AcharyBackground: Blood brain barrier and Alzheimer's disease are interrelated. This interrelation is detected by physicochemical methods, pharmacological and electrophysiological analyses. Nature of the phenomenon is extremely complex. The description of this interrelation in mathematical terms is a very important task. Objective: The systematization of facts, which are described in the literature and related t Read More
-
-
-
In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease
Parkinson's Disease (PD) is a long-term neurodegenerative brain disorder that mainly affects the motor system. The causes are still unknown, and even though currently there is no cure, several therapeutic options are available to manage its symptoms. The development of novel antiparkinsonian agents and an understanding of their proper and optimal use are, indeed, highly demanding. For the last decades, L-3, Read More
-
-
-
Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?
Authors: Riccardo Zanni, Ramon Garcia-Domenech, Maria Galvez-Llompart and Jorge GalvezBackground: The last decade was characterized by a growing awareness about the severity of dementia in the field of age-related and no age-related diseases and about the importance to invest resources in the research of new, effective treatments. Among the dementias, Alzheimer's plays a substantial role because of its extremely high incidence and fatality. Several pharmacological strategies have been tried but still Read More
-
-
-
Computer-aided Drug Design Applied to Parkinson Targets
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by debilitating motor deficits, as well as autonomic problems, cognitive declines, changes in affect and sleep disturbances. Although the scientific community has performed great efforts in the study of PD, and from the most diverse points of view, the disease remains incurable. The exact mechanism underlying its progression is uncl Read More
-
-
-
3D-QSAR and in-silico Studies of Natural Products and Related Derivatives as Monoamine Oxidase Inhibitors
Authors: Priyanka Dhiman, Neelam Malik and Anurag KhatkarBackground: The computational development of human monoamine oxidase (MAO) inhibitors led to advancement in drug design and the treatment of many neurodegenerative diseases and neuropsychiatric disorders. The computational development of human monoamine oxidase (MAO) inhibitors led to advancement in drug design and the treatment of many neurodegenerative diseases and neuropsychiatric disorders. Di Read More
-
Volumes & issues
-
Volume 23 (2025)
-
Volume 22 (2024)
-
Volume 21 (2023)
-
Volume 20 (2022)
-
Volume 19 (2021)
-
Volume 18 (2020)
-
Volume 17 (2019)
-
Volume 16 (2018)
-
Volume 15 (2017)
-
Volume 14 (2016)
-
Volume 13 (2015)
-
Volume 12 (2014)
-
Volume 11 (2013)
-
Volume 10 (2012)
-
Volume 9 (2011)
-
Volume 8 (2010)
-
Volume 7 (2009)
-
Volume 6 (2008)
-
Volume 5 (2007)
-
Volume 4 (2006)
-
Volume 3 (2005)
-
Volume 2 (2004)
-
Volume 1 (2003)
Most Read This Month
Article
content/journals/cn
Journal
10
5
false
en
